ReviewNature reviews. Nephrology2012
B-cell depletion in the treatment of lupus nephritis.
Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.Annals of the rheumatic diseases · 2022Trial
- Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review-NEW Group (Neutropenic Events Working Group).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- CD21 primes extrafollicular differentiation of autoreactive B cells in a TLR7-driven lupus model.Science immunology · 2025Article
- Molecular and Cellular Mediators of Renal Fibrosis in Lupus Nephritis.International journal of molecular sciences · 2025Review
- Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study.Lupus science & medicine · 2025Article
- 2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus.Signal transduction and targeted therapy · 2024Article
- The advance of single cell transcriptome to study kidney immune cells in diabetic kidney disease.BMC nephrology · 2024Review
- Reciprocal regulation of SIRT1 and AMPK by Ginsenoside compound K impedes the conversion from plasma cells to mitigate for podocyte injury in MRL/Journal of ginseng research · 2024Article
- Lupus-associated innate receptors drive extrafollicular evolution of autoreactive B cells.bioRxiv : the preprint server for biology · 2024Article
- An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia.Archives of medical science : AMS · 2024Article
- Article
- Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases.Frontiers in oncology · 2023Review
- Thrombotic microangiopathy mediates poor prognosis among lupus nephritisFrontiers in immunology · 2022Article
- The Advances of Single-Cell RNA-Seq in Kidney Immunology.Frontiers in physiology · 2021Review
- Identification of the tubulointerstitial infiltrating immune cell landscape and immune marker related molecular patterns in lupus nephritis using bioinformatics analysis.Annals of translational medicine · 2020Article
- MicroRNA-146a-deficient mice develop immune complex glomerulonephritis.Scientific reports · 2019Article
- Excessive miR-152-3p Results in Increased BAFF Expression in SLE B-Cells by Inhibiting the KLF5 Expression.Frontiers in immunology · 2019Article
- B Cell-Related Circulating MicroRNAs With the Potential Value of Biomarkers in the Differential Diagnosis, and Distinguishment Between the Disease Activity and Lupus Nephritis for Systemic Lupus Erythematosus.Frontiers in immunology · 2018Article
- Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is clinically heterogeneous and affects multiple organs. Lupus nephritis is the most frequent severe manifestation of SLE. Conventional immunosuppressive therapy has increased the life expectancy of patients diagnosed with lupus nephritis, but only 70-80% of patients respond to this treatment and its adverse effects are considerable. B cells are central to the pathogenesis of SLE and are, therefore, an attractive therapeutic target. B-cell depletion has been used successfully to treat other autoimmune diseases, such as rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis, and many case reports and small nonrandomized trials of B-cell-depleting agents in patients with lupus nephritis have reported positive results. By contrast, two large placebo-controlled trials designed to investigate the efficacy of the B-cell-depleting agents rituximab and ocrelizumab as a treatment for lupus nephritis, failed to meet their primary efficacy end points (LUNAR and BELONG, respectively). This Review discusses the current evidence on the use of B-cell depletion in the treatment of lupus nephritis, which is derived from case studies and clinical trials including a total of over 800 patients.
Indexed as
Identifiers
22801948What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.